3 FTSE 100 shares to buy before the market rebounds

This year, many FTSE 100 stocks have fallen 20% or more. Edward Sheldon highlights three shares he’d buy before global stock markets recover.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Smartly dressed middle-aged black gentleman working at his desk

Image source: Getty Images

The FTSE 100 has held up well in 2022, relative to other major stock market indexes. Year to date, it’s only down a few percent.

Yet this doesn’t tell the full story. That’s because this year the Footsie has been propped up by oil stocks such as Shell and BP. A closer look reveals that many stocks within the index are down 20%, or more.

I don’t know exactly when these beaten-up FTSE 100 stocks will recover. But history shows we are likely to see a rebound at some stage. With that in mind, here’s a look at three Footsie stocks I’d buy for my portfolio now, before the stock market recovers.

Smith & Nephew

One of my top picks in the FTSE 100 right now is Smith & Nephew (LSE: SN), the healthcare company that specialises in joint replacements.

There are several reasons I’m bullish here. One is that backlogs for joint replacement surgery remain high after Covid-19. This positions the company well for growth in the years ahead.

Another is that the world’s ageing population should support growth over the next decade. According to the World Health Organisation, by 2030, one in six people globally will be 60 or over. This should create high demand for joint replacements.

Key risks here include further lockdowns and supply chain issues. With the stock trading at 14 times next year’s earnings however, I think a lot of this is priced in.

Experian

I also like the look of credit data specialist Experian (LSE: EXPN) right now. To my mind, this is one the FTSE 100’s best ‘quality’ growth stocks.

In recent years, Experian has shifted from just selling data to selling data with decisioning tools. This has helped boost growth. Last year for example, revenue rose 17%. Looking ahead, analysts expect the company to keep growing at a healthy clip. This year and next, they expect top-line growth of around 8%.

One thing that stands out to me here is that the company is buying back its own shares. In May, it announced a new $175m buyback. This should help boost earnings per share over time.

Of course, if technology shares continue to fall, Experian could underperform. The stock currently trades at just 22 times this year’s earnings forecast however. And at that multiple, I see a margin of safety.

Rightmove

Finally, I’d also buy shares in Rightmove (LSE: RMV) today. It operates the UK’s largest property website.

Rightmove is another quality growth company. Not only is it the leader in its industry by a wide margin, thanks to its strong brand, but it’s also extremely profitable. Last year, for example, its return on capital was about 280%, which is phenomenal.

Additionally, the company has a great track record in terms of revenue and earnings growth and wealth generation for shareholders.

It’s worth pointing out that Rightmove’s CEO is set to leave the company next year, after five years at the helm. This adds uncertainty. Another risk to consider is economic conditions in the UK. A prolonged downturn could see estate agents go out of business. This could impact Rightmove’s revenues.

With the stock currently way off its 52-highs, I think the long-term risk/reward is favourable for me though. The stock’s P/E ratio of 24 seems quite reasonable, to my mind.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Edward Sheldon has positions in Experian, Rightmove, and Smith & Nephew. The Motley Fool UK has recommended Experian, Rightmove, and Smith & Nephew. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »